Quick Facts

• Targeted Condition: Addresses certain viral infections.
• Primary Application: Supports the management of mild to moderate disease in specified populations.
• Benefit Profile: May help limit disease progression in individuals with risk factors for severe illness.

---

Remide is a prescription medication utilized in therapeutic regimens for certain viral infections. Its primary use is focused on supporting the management of mild to moderate disease, particularly in adult patients and pediatric patients who are at a higher risk of progressing to a severe condition. This medication is administered to individuals who have tested positive for the targeted infection and whose symptoms began within a specific timeframe.

The therapeutic approach of Remide aims to assist the body's processes in inhibiting the virus from multiplying. This action may help limit disease progression and the potential for hospitalization when initiated early in the course of the illness. As part of a comprehensive care plan, Remide is employed to achieve clinical improvement.

Eligibility Map: Who Can and Cannot Use Remide – Official Regulatory Information

Category	Official Regulatory Statements
Populations for whom use is allowed (as stated in label)	Adults and pediatric patients (birth to <18 years of age) weighing ge 1.5 kg who are hospitalized, OR not hospitalized and are at high risk for progression to severe disease [Source: FDA, EMA].
Populations for whom use is not recommended (if applicable)	Co-administration with chloroquine phosphate or hydroxychloroquine sulfate is not recommended due to risk of reduced antiviral activity [Source: FDA, EMA].
Populations for whom use is contraindicated	Patients with a history of clinically significant hypersensitivity reactions to Remide or any component of the product [Source: FDA, EMA].
Age-related eligibility rules	Minimum Weight: ge 1.5 kg (from birth) [Source: FDA]. Older Adults: No specific dose adjustment is required [Source: EMA].
Condition-specific eligibility rules	Hepatic Impairment: Should not be initiated if baseline ALT levels are ge 10 imes ULN [Source: FDA]. Renal Impairment: No dose adjustment is recommended for any degree of renal impairment [Source: FDA].
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Use only if the potential benefit justifies the potential risk for the mother and fetus [Source: FDA, EMA]. Lactation: Remide can pass into breast milk; decision requires a benefit/risk assessment [Source: FDA].

---

Eligibility Classifications (High-Level)

Classification	Official Definition (Regulatory Wording)
Eligibility severity classification (as defined in official documents)	Contraindicated (Hypersensitivity); Not Recommended (Co-administration/High Baseline ALT); Conditional (Pregnancy/Lactation/Severe Hepatic Risk) [Source: FDA, EMA].
Regulatory basis (EMA / FDA / etc.)	Full approval from FDA (United States) and EMA (European Union) [Source: FDA, EMA].
Eligibility-context constraints (as defined in official documents)	Must be for patients at high risk for progression to severe disease (non-hospitalized indication) OR patients who are hospitalized [Source: FDA, EMA].

---

Resulting Eligibility Structure

Official eligibility statements:

• Remide is contraindicated in patients with a history of clinically significant hypersensitivity reactions to the drug or any of its components.
• The medicine is approved for adults and pediatric patients from birth and weighing ge 1.5 kg.
• Non-hospitalized patients must be classified as at high risk for progression to severe disease.
• Treatment should not be initiated if baseline ALT levels are ge 10 times the upper limit of normal.
• Use during pregnancy and lactation is permitted only after a formal assessment that the potential benefit justifies the potential risk.

Connection to the overall eligibility profile

The official regulatory documents define who can and cannot use Remide by establishing absolute contraindications based on past hypersensitivity, setting minimum age and weight thresholds for the pediatric population, and implementing conditional restrictions related to liver function status and specific drug combinations. Eligibility for non-hospitalized patients is explicitly bound by the patient's risk profile for developing severe illness.

Official Interaction Profile for Remide (Rebamipide)

This section outlines interactions with other medicines and products that are formally documented in government regulatory sources, such as official prescribing information.

Regulatory documents indicate that Remide (Rebamipide) has a low overall potential for clinically significant drug-drug interactions. It is primarily excreted as the unchanged drug, suggesting a limited risk of interaction mediated by major hepatic enzymes (e.g., Cytochrome P450) or drug transporters.

Documented Interactions

Substance / Condition	Official Interaction Description
Co-administered Medicines	No specific medicinal products are formally listed as interacting or contraindicated.
Food	Administration after a meal delays the rate of absorption ( T max) but does not affect the total systemic exposure (bioavailability).
Alcohol	Excessive alcohol consumption should be avoided, as it may increase the risk of certain side effects or lead to a potential interaction.

Population-Specific Pharmacokinetic Notes

The regulatory profile highlights altered drug exposure in specific patient populations, which is an important consideration for management:

• Renal Impairment: Patients with renal impairment exhibit a higher plasma concentration and a longer elimination half-life for the drug compared to healthy subjects.
• Severe Liver Dysfunction: Individuals with severe liver dysfunction may experience altered drug metabolism and elimination.

No mandatory timing separation requirements for co-administration with other medicinal products are listed in the regulatory documents.

The mechanism of action for Remide (Rebamipide) is characterized by a multi-targeted approach to enhance local mucosal defense factors, structurally distinct from direct acid suppression.

Reinforcing the Gastric Barrier and Microcirculation

The drug works by inducing the expression of the COX-2 enzyme in the mucosal cells, which increases the local production of protective prostaglandins ( PGE2). These prostaglandins are essential mediators that increase microcirculation to the lining and stimulate the secretion of a thick, defensive layer of mucus and bicarbonate, which contributes to a higher functional integrity of the tissue against aggressive intraluminal factors.

Accelerating Epithelial Repair and Regeneration

Remide promotes the accelerated repair of the mucosal surface by upregulating crucial Epidermal Growth Factors ( EGF). This action drives the rapid proliferation and migration of epithelial cells, which supports the rapid closure and restoration of tissue integrity following cellular damage, resulting in the re-establishment of the lining's structural integrity.

Anti-Inflammatory and Antioxidant Cytoprotection

The molecule provides direct cytoprotection by acting as a scavenger of Reactive Oxygen Species ( ROS), which are damaging free radicals, thereby reducing the impact of oxidative stress at the cellular level. Furthermore, it suppresses the NF-kappa B pathway, reducing the production of damaging inflammatory cytokines ( IL-8), which contributes to the control of inflammation-related tissue damage.

How to Use Remide

This section outlines the usage instructions for Remide (Rebamipide), focusing on the route of administration, dosage, frequency, and administration conditions.

---

Administration and Dosage Regimen

Remide is supplied as a 100 mg film-coated tablet and is administered exclusively via the oral route.

The standard dosage for adults is:

Administration Feature	Instruction
Single Dose	100 mg (one tablet)
Dosing Frequency	Three times daily (TID)
Total Daily Dose	300 mg

This regimen is used for the management of conditions such as acute gastritis and gastric ulcers.

Timing and Special Instructions

Guidance regarding administration context and timing includes:

• With or Without Food: Remide may be taken with or without food, as food does not affect the drug's overall bioavailability.
• Missed Dose: If a dose is missed, patients are instructed to skip the missed dose and take the next dose at the regularly scheduled time; they should not take two doses at once.
• Stopping Treatment: The medication should not be stopped unless advised to do so by a healthcare professional, ensuring the full prescribed course is completed.

Population-Specific Use

Considerations for certain populations include:

• Pediatric Use: The safety and effectiveness of Remide have not been established in children.
• Renal Impairment: Caution is noted for patients with renal impairment due to the observation of higher plasma concentrations and a prolonged half-life of the drug in this group, though explicit dose adjustment recommendations are not uniformly provided.

Research Evidence / Overview of Studies

How the Drug was Studied

Research investigated the potential activity of Remide. Early-phase studies explored the drug’s process and assessed the optimal dosage range for subsequent clinical trials. The drug’s potential activity involves pathways related to inflammation and cellular signaling, which were the focus of initial evaluation.

---

Key Clinical Trial Findings

Monotherapy

Key findings from clinical trials highlight that studies reported a reduction in disease activity in certain participants. This treatment was generally reported as tolerable. Results were mixed regarding the duration of the observed effects across different patient groups, underscoring the need for individualized assessment.

• A Phase 3 randomized, controlled trial (RCT) examined Remide's activity in 450 adult participants over six months.
• Results indicated that participants receiving the active treatment demonstrated a measured difference in their scores on the primary outcome measure compared to those receiving placebo.
• A study focusing on long-term safety examined the drug’s profile over two years; research noted potential side effects were observed, especially at higher doses.

Combined Therapy

Studies evaluated whether combining Remide with standard therapy affected pain and mobility when compared to standard therapy alone. The analysis explored whether the combination was associated with differences in observed outcomes.

• Differences in outcomes observed in a subgroup receiving the combination therapy suggest that further research is warranted to fully understand this approach for severe cases.

---

Subgroups and Specific Populations

Pediatric Patients (Ages 6-17)

Evidence remains limited on the use of this drug in children. One small-scale pilot study assessed the drug’s activity in 30 participants in this age group. The initial data did not report safety signals beyond those already known compared to the adult population.

Elderly Patients (Ages 65+)

Initial research explored Remide's profile in this population, but further data is being collected to understand long-term outcomes. An observational cohort study reviewed the health records of 150 elderly patients who received the drug; adverse events reported were similar to those seen in the general adult population.

Common questions about Remide (FAQ)

---

Q: Can Remide be crushed or chewed?

Remide is supplied as a film-coated tablet intended for oral administration. The official regulatory documents identify the product form without specifying whether the tablets can be crushed or chewed.

Q: What happens if I accidentally take two doses at once?

Official instructions state that patients should not take two doses at once. While the label does not fully detail the effects of a minor overdose, information regarding the management of a significant overdose is typically available in the full prescribing documents.

Q: How long does Remide take to start working or for symptoms to improve?

Official pharmacokinetic data indicates the active ingredient typically reaches its peak concentration in the blood around two hours after administration. However, the full product information notes that clinical trials evaluating the product for conditions like gastric ulcers measure healing over longer periods, such as eight weeks.

Q: Is there a maximum duration for Remide treatment?

The official prescribing information for the product does not always specify a universal maximum treatment duration for all indicated conditions. However, clinical studies often evaluate the product's profile over periods up to six months.

Q: How does Remide actually heal the stomach lining?

Remide is classified as a specialized gastrointestinal agent and mucoprotective molecule that works by enhancing the body’s natural protective factors. According to product information, this involves increasing the production of protective mucus, improving blood flow to the lining, and promoting cell repair.

Q: What should I do if I forget to take a dose?

The official drug information sheet states that a missed dose should be skipped entirely. The next dose is to be taken at its regularly scheduled time. Patients are specifically instructed not to double the dose to make up for the missed one.

How to Store and Dispose of Remide?

Remide (Rebamipide) tablets must be stored according to specific regulatory guidelines to maintain their stability and safety.

---

Official Storage Requirements

Constraint	Requirement
Temperature	Store at a temperature not exceeding 30 C.
Protection	Keep the medicine protected from direct sunlight, heat, and moisture.
Safety	Must be kept out of the sight and reach of children.
Packaging	Keep the tablets in their original packaging until ready for use.

---

Disposal of Unused Medicine

Unused, expired, or leftover Remide must be disposed of in a manner that follows local regulations. The medicine should be kept away from drains, water courses, or the soil to prevent environmental release. Do not discard the tablets into wastewater or household trash unless specifically instructed by local drug take-back programs.